TAKARA BIO INC. Financials Takara Bio Inc. Deutsche Boerse AG
Equities
TF2
JP3460200003
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.55 EUR | +0.77% |
|
+5.65% | -14.94% |
| 05-10 | Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024 | CI |
| 03-18 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 268,647 | 357,394 | 269,851 | 208,680 | 116,803 | 141,609 | - | - |
| Enterprise Value (EV) 1 | 249,501 | 332,542 | 247,265 | 157,805 | 82,355 | 141,609 | 141,609 | 141,609 |
| P/E ratio | 70.3 x | 37.4 x | 13.6 x | 13 x | 78.9 x | 38.7 x | 33.1 x | 28.2 x |
| Yield | 0.36% | 0.54% | 1.47% | 2.42% | 1.75% | 1.53% | 1.7% | 1.9% |
| Capitalization / Revenue | 7.77 x | 7.75 x | 3.99 x | 2.67 x | 2.68 x | 2.99 x | 2.8 x | 2.65 x |
| EV / Revenue | 7.77 x | 7.75 x | 3.99 x | 2.67 x | 2.68 x | 2.99 x | 2.8 x | 2.65 x |
| EV / EBITDA | 27.7 x | 20.2 x | 8.19 x | 8.28 x | 14.7 x | 15.1 x | 13.6 x | 12.4 x |
| EV / FCF | 114 x | 35.2 x | -3,138 x | 6.91 x | -10.3 x | 17.7 x | 86.2 x | 45.2 x |
| FCF Yield | 0.88% | 2.84% | -0.03% | 14.5% | -9.7% | 5.65% | 1.16% | 2.21% |
| Price to Book | 4.04 x | 4.82 x | 2.81 x | 1.86 x | 1.05 x | 1.26 x | 1.25 x | 1.23 x |
| Nbr of stocks (in thousands) | 120,416 | 120,416 | 120,416 | 120,416 | 120,416 | 120,416 | - | - |
| Reference price 2 | 2,231 | 2,968 | 2,241 | 1,733 | 970.0 | 1,176 | 1,176 | 1,176 |
| Announcement Date | 5/14/20 | 5/13/21 | 5/12/22 | 5/11/23 | 5/10/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 34,565 | 46,086 | 67,699 | 78,142 | 43,505 | 47,412 | 50,546 | 53,407 |
| EBITDA 1 | 9,691 | 17,658 | 32,956 | 25,190 | 7,922 | 9,403 | 10,394 | 11,454 |
| EBIT 1 | 6,274 | 13,952 | 28,902 | 20,541 | 3,003 | 5,070 | 5,946 | 6,936 |
| Operating Margin | 18.15% | 30.27% | 42.69% | 26.29% | 6.9% | 10.69% | 11.76% | 12.99% |
| Earnings before Tax (EBT) 1 | 5,433 | 13,552 | 27,532 | 21,224 | 2,853 | 5,066 | 5,963 | 6,978 |
| Net income 1 | 3,819 | 9,547 | 19,849 | 16,012 | 1,480 | 3,658 | 4,284 | 5,024 |
| Net margin | 11.05% | 20.72% | 29.32% | 20.49% | 3.4% | 7.72% | 8.47% | 9.41% |
| EPS 2 | 31.72 | 79.29 | 164.8 | 133.0 | 12.30 | 30.38 | 35.58 | 41.73 |
| Free Cash Flow 1 | 2,356 | 10,165 | -86 | 30,204 | -11,332 | 8,006 | 1,642 | 3,136 |
| FCF margin | 6.82% | 22.06% | -0.13% | 38.65% | -26.05% | 16.89% | 3.25% | 5.87% |
| FCF Conversion (EBITDA) | 24.31% | 57.57% | - | 119.9% | - | 85.14% | 15.8% | 27.37% |
| FCF Conversion (Net income) | 61.69% | 106.47% | - | 188.63% | - | 218.86% | 38.34% | 62.41% |
| Dividend per Share 2 | 8.000 | 16.00 | 33.00 | 42.00 | 17.00 | 18.00 | 20.00 | 22.33 |
| Announcement Date | 5/14/20 | 5/13/21 | 5/12/22 | 5/11/23 | 5/10/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 18,115 | 17,393 | 28,693 | 31,551 | 14,108 | 22,040 | 36,148 | 14,102 | 18,485 | 32,587 | 27,619 | 17,936 | 45,555 | 9,176 | 9,940 | 19,116 | 10,618 | 13,771 | 24,389 | 9,594 | 10,274 | 19,868 | 11,323 | 15,231 | 26,553 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 3,239 | 3,736 | - | 14,105 | 5,821 | 8,976 | 14,797 | 4,537 | 6,333 | 10,870 | 8,533 | 1,138 | 9,671 | 423 | 987 | 1,410 | -1,074 | 2,667 | 1,593 | -175 | 819 | 644 | 913 | 2,586 | 3,499 |
| Operating Margin | 17.88% | 21.48% | - | 44.71% | 41.26% | 40.73% | 40.93% | 32.17% | 34.26% | 33.36% | 30.9% | 6.34% | 21.23% | 4.61% | 9.93% | 7.38% | -10.11% | 19.37% | 6.53% | -1.82% | 7.97% | 3.24% | 8.06% | 16.98% | 13.18% |
| Earnings before Tax (EBT) 1 | 2,483 | 3,281 | - | 14,203 | 5,911 | 7,418 | 13,329 | 5,479 | 6,352 | 11,831 | 8,487 | 906 | 9,393 | 505 | 1,083 | 1,588 | -1,088 | 2,353 | 1,265 | -259 | 734 | 475 | 822 | 2,519 | 3,341 |
| Net income 1 | 1,744 | 2,274 | - | 10,009 | 4,355 | 5,485 | 9,840 | 3,907 | 4,631 | 8,538 | 6,057 | 1,417 | 7,474 | 319 | 765 | 1,084 | -930 | 1,326 | 396 | -539 | 454 | -85 | 542 | 2,239 | 2,781 |
| Net margin | 9.63% | 13.07% | - | 31.72% | 30.87% | 24.89% | 27.22% | 27.71% | 25.05% | 26.2% | 21.93% | 7.9% | 16.41% | 3.48% | 7.7% | 5.67% | -8.76% | 9.63% | 1.62% | -5.62% | 4.42% | -0.43% | 4.79% | 14.7% | 10.47% |
| EPS 2 | 14.49 | 18.89 | - | 83.12 | 36.17 | 45.55 | 81.72 | 32.45 | 38.46 | 70.91 | 50.30 | 11.76 | 62.06 | 2.650 | 6.350 | 9.000 | -7.720 | 11.02 | 3.300 | -4.500 | 3.800 | -0.7000 | 4.500 | 18.60 | 23.10 |
| Dividend per Share | 8.000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.00 | 17.00 | - | - | - | - | - | 17.00 |
| Announcement Date | 5/14/20 | 11/10/20 | 5/13/21 | 11/9/21 | 2/10/22 | 5/12/22 | 5/12/22 | 8/4/22 | 11/10/22 | 11/10/22 | 2/9/23 | 5/11/23 | 5/11/23 | 8/8/23 | 11/9/23 | 11/9/23 | 2/14/24 | 5/10/24 | 5/10/24 | - | - | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 19,146 | 24,852 | 22,586 | 50,875 | 34,448 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 2,356 | 10,165 | -86 | 30,204 | -11,332 | 8,006 | 1,643 | 3,136 |
| ROE (net income / shareholders' equity) | 5.9% | 13.6% | 23.3% | 15.4% | 1.3% | 3.22% | 3.63% | 4.16% |
| ROA (Net income/ Total Assets) | 8.69% | 17.2% | 27.7% | 16.9% | 2.72% | 5% | - | - |
| Assets 1 | 43,939 | 55,546 | 71,651 | 94,806 | 54,431 | 73,160 | - | - |
| Book Value Per Share 2 | 552.0 | 616.0 | 796.0 | 932.0 | 926.0 | 930.0 | 941.0 | 955.0 |
| Cash Flow per Share 2 | 56.90 | 107.0 | 195.0 | 167.0 | 48.70 | 77.40 | 86.60 | 91.30 |
| Capex 1 | 3,983 | 8,673 | 12,356 | 5,747 | 12,778 | 10,000 | 6,000 | 5,000 |
| Capex / Sales | 11.52% | 18.82% | 18.25% | 7.35% | 29.37% | 21.09% | 11.87% | 9.36% |
| Announcement Date | 5/14/20 | 5/13/21 | 5/12/22 | 5/11/23 | 5/10/24 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,176
JPY
Average target price
1,567
JPY
Spread / Average Target
+33.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.74% | 47.96B | |
| -0.47% | 42.45B | |
| +43.96% | 41.47B | |
| +25.40% | 31.6B | |
| +17.96% | 28.63B | |
| -4.47% | 28.03B | |
| +50.73% | 14.56B | |
| +42.56% | 14.14B | |
| +1.46% | 12.58B |
- Stock Market
- Equities
- 4974 Stock
- TF2 Stock
- Financials Takara Bio Inc.
